Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Change in lipid profiles, AI, mFRS, and IR in patients receiving biologic or biologic-naïve therapy

From: Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis

  Adalimumab (n = 32) Etanercept (n = 16) Tocilizumab (n = 24) Without biologic (n = 20)
Total cholesterol, mg/dL     
  Baseline 212.3 ± 5.8 195.3 ± 9.8 191.8 ± 5.3 209.6 ± 11.2
  Week 24 212.1 ± 5.6 191.0 ± 7.9 211.5 ± 6.8* 199.5 ± 8.6
HDL-C, mg/dL     
  Baseline 73.0 ± 2.7 67.5 ± 4.1 67.7 ± 3.3 70.4 ± 4.4
  Week 24 77.1 ± 3.8 71.7 ± 4.0 72.1 ± 4.0 70.8 ± 5.2
LDL-C, mg/dL     
  Baseline 131.3 ± 5.3 118.4 ± 8.9 119.2 ± 5.5 123.4 ± 9.1
  Week 24 127.0 ± 5.6 117.0 ± 7.4 134.3 ± 6.5* 114.2 ± 6.0
Triglyceride, mg/dL     
  Baseline 105.6 ± 8.3 129.8 ± 21.1 118.8 ± 9.8 86.9 ± 9.3
  Week 24 105.7 ± 7.1 106.4 ± 12.0 135.5 ± 11.4* 88.9 ± 9.6
Atherogenic index     
  Baseline 3.00 ± 0.11 3.05 ± 0.29 2.94 ± 0.12 3.11 ± 0.18
  Week 24 2.91 ± 0.14 2.75 ± 0.16 3.11 ± 0.16 3.01 ± 0.20
Modified FRS     
  Baseline 3.52 ± 0.65 4.22 ± 1.44 3.48 ± 0.91 3.43 ± 0.93
  Week 24 3.42 ± 0.72 4.22 ± 1.40 4.04 ± 0.97* 3.25 ± 0.79
Insulin resistance     
  Baseline 2.75 ± 0.29 2.90 ± 0.53 2.97 ± 0.38 2.28 ± 0.34
  Week 24 1.76 ± 0.39* 1.71 ± 0.26** 1.99 ± 0.25** 1.77 ± 0.18
  1. Data are presented as mean ± standard error of mean. *P <0.05, **P <0.005, versus before treatment, determined by Wilcoxon signed rank test. FRS, Framingham risk score; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.